Registration for a live webinar on 'Innate immunity, inflammation and cancer' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- General Virology
-
46 min
1. Principles of virology- Prof. Vincent Racaniello
-
36 min
2. Antiviral drugs (non-HIV)- Prof. Megan Shaw
-
36 min
3. The type I interferon system and viruses- Dr. Adolfo Garcia-Sastre
-
45 min
4. Immune responses to viruses- Prof. Paul Klenerman
- Emerging Pathogens
-
29 min
5. Emerging or newly discovered viral causes of acute lower respiratory tract infections worldwide- Dr. Marietjie Venter
- Mrs. Orienka Hellferscee
-
37 min
6. Emerging respiratory viruses - discoveries between 2001 and 2005- Prof. Ron Fouchier
-
28 min
7. Usage of vaccines and therapeutics in public health emergencies 1- Prof. Gary Kobinger
-
39 min
8. Usage of vaccines and therapeutics in public health emergencies 2- Prof. Gary Kobinger
-
50 min
9. Influenza virus pandemics: past and future- Prof. Peter Palese
-
63 min
10. SARS-CoV and other emerging coronaviruses- Prof. Ralph Baric
-
36 min
11. Dengue, Zika and Chickungunya viruses- Prof. Ana Fernandez-Sesma
-
41 min
12. Biodefense challenges- Dr. David Franz
- Important Pathogens and their Diseases
-
38 min
13. Natural history and pathogenesis of herpes virus infections- Prof. Richard Whitley
-
40 min
14. Cytomegalovirus biology- Prof. Domenico Tortorella
-
46 min
15. Hepatitis C virus: discovery, cure and protection- Dr. Matthew Evans
-
32 min
16. Fundamentals of HIV biology- Prof. Viviana Simon
-
44 min
17. Measles- Prof. Diane E. Griffin
- New Frontiers
-
45 min
-
55 min
-
30 min
20. Viruses as anticancer weapons- Prof. Roberto Cattaneo
-
48 min
21. Novel approaches to diagnosis of viral infections- Prof. W. Ian Lipkin
-
31 min
22. Elite controllers of HIV: from discovery to future therapies- Prof. Bruce Walker
- Archived Lectures *These may not cover the latest advances in the field
-
43 min
23. Principles of virology I- Prof. Richard Condit
-
43 min
24. Principles of virology II- Prof. Richard Condit
-
36 min
25. Complex DNA viruses: herpes virus- Dr. John Blaho
-
38 min
26. Adeno-associated viruses (AAV)- Prof. Kenneth Berns
-
60 min
27. Poxviruses: smallpox (variola), vaccinia and monkeypox- Prof. Paula Traktman
-
26 min
28. Can HPV testing be the sole primary cervical screening modality?- Prof. Jack Cuzick
-
29 min
29. From viruses to oncolytics- Prof. Roberto Cattaneo
-
38 min
30. Non HIV antivirals- Prof. Mary Klotman
-
42 min
31. Gastroenteritis viruses- Prof. Mary Estes
-
46 min
32. Biodefense challenges- Dr. Connie Schmaljohn
-
32 min
-
49 min
34. The past, present and future of vaccination- Prof. Stanley Plotkin
-
41 min
35. Filoviruses- Dr. Christopher Basler
-
41 min
36. Bunyaviruses- Prof. Richard Elliott
-
41 min
37. The immunobiology of HIV- Prof. Norman Letvin
-
59 min
38. Hepatitis C and HCV- Prof. Stanley Lemon
Printable Handouts
Navigable Slide Index
- Introduction
- Disclosure
- Outline of presentation
- Cancers attributable to HPV infection
- HPV types associated with cervical cancer
- Progression of cervical HPV infections to cancer
- Natural history of cervical HPV infection
- Key features of HPV pathogenesis
- Genital warts
- Laboratory of cellular oncology, CCR, NCI
- Developing preventive HPV vaccine challenges
- A prophylactic vaccine
- Formation of papillomavirus virions
- L1 self-assembles to form virus-like particles
- L1 VLP induction of neutralizing antibodies
- Systemic VLP vaccination in animal models
- Two HPV VLP vaccines are under development
- Merck: phase III prophylactic efficacy results
- Possible long term protection by HPV vaccine
- Cross-protection against other HPV types
- Preventing HPV cervical disease efficacy
- HPV life cycle
- How could vaccine prevent mucosal infection
- How could vaccine prevent cutaneous infection
- L1 VLPs are unlikely to be directly therapeutic
- Will the vaccines influence prevalent infection?
- Outstanding medical issues
- Regulatory status of HPV VLP vaccines
- Gardasil phase III adolescent study
- Percentage of sexually active teenagers in USA
- Disease progression by HPV status at entry
- We can't give up screening
- Cervical cancer prevention by Pap screening
- HPV-based cervical cancer prevention strategy
- HPV vaccination in developing nations
- Limitations of current VLP vaccines
- Potential reduction in cervical cancer
- Papillomaviruses neutralized by BPV1 L2
- Vaccination with L1-Salmonella live vaccine
- Summary and conclusions
Topics Covered
- Cervical cancer is attributable to multiple HPV types; HPV16 predominates
- Cervical cancer: time line of cervical HPV infections, progression and natural history
- Key features of HPV pathogenesis
- Challenges to development of a preventive HPV vaccine
- A prophylactic vaccine
- Formation of papillomavirus virions
- Two distinct HPV VLP vaccines are under commercial development
- Partial crossprotection against incident infection by other high risk HPV types
- Overall efficacy in preventing HPV cervical disease attributable to incident infection
- HPV life cycle
- How could IM injection of a VLP vaccine prevent mucosal or cutaneous infection at the cervix?
- Outstanding medical issues
- Regulatory status of HPV VLP vaccines
- Pap smear screening without vaccination would prevent more cervical cancer deaths than HPV16/18 vaccination without pap screening
- Limitations of current VLP vaccines
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Lowy, D. (2007, October 1). Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 20, 2024, from https://hstalks.com/bs/369/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Douglas Lowy has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Papillomaviruses and HPV vaccination to prevent cervical cancer and other HPV-associated diseases
A selection of talks on Microbiology
Hide